NeuroVive: Interim report 1 Jan. 2015 till 31 Mar. 2015
Capital raising characterizes NeuroVive ́s first quarter
Press releases
NeuroVive Pharmaceutical publishes English version of annual report for 2014
NeuroVive Pharmaceutical AB (publ) today announced that the English version of the annual report for 2014 is now available on the company's website www.neurovive.com.The annual report can also be acce ...
NeuroVive: Year-End Report 1 Jan. 2014 till 31 Dec. 2014
Fourth Quarter (1 Oct. 2014 - 31 Dec. 2014) · Net revenues were SEK 0 (0) and other operating income was SEK 8,000 (12,000). · Loss before tax was SEK -17,346,000 (9,169,000). · Earnings per share* we ...
NeuroVive: Interim Report 1 Jan. 2014 to 30 Sep. 2014
Important outlicensing deal and increased focus on core operations
NeuroVive: Interim Report 1 Jan. 2014 to 30 Jun. 2014
NeuroVive's research wins award at international research symposium
NeuroVive: Interim report 1 Jan. 2014 till 31 Mar. 2014
Successful rights issue and final patient treated in phase III study on CicloMulsion®
NeuroVive Pharmaceutical’s 2013 Annual Report now available
Today, NeuroVive Pharmaceutical AB (publ) announced that the Annual Report for 2013 is available as PDF at www.neurovive.com, and can be read via the link below. The available report is in Swedish. An ...
NeuroVive: Year-End Report 1 Jan. 2013 till 31 Dec. 2013
NeuroVive consolidates positioning as leading mitochondrial medicine company
NeuroVive: Interim Report 1 Jan. 2013 till 30 Sep. 2013
Increased interest in NeuroVives product portfolio with cyclophilin inhibitors and energy regulators
NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013
Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 - 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (31 ...
NeuroVive: Interim report 1 Jan. 2013 till 31 Mar. 2013
The listing on Nasdaq OMX creates possibilities for the future